Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma

NCT03060356 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT03060356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03060356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Terminated
Start date
December 21, 2016
Completion date
March 27, 2020
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, malignant melanoma